The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.
The researchers used the tool to look at the role of miRNAs in viral infection, but believe it has potential for studying miRNA in many other contexts.
The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.
Members of TCGA characterized papillary renal cell carcinomas, uncovering two main tumor groups and several more prognostically informative subtypes.
In Nature this week: how CRISPR/Cas9 homes in on target, miRNAs involved in cholesterol and triglyceride regulation, and more.
The firm’s increase in sales included a 25 percent jump in sales of Rosetta's core microRNA-based diagnostic assays over the first half of 2014.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
In Cell this week: method to examine DNA methylation patterns, molecular features of lobular breast cancer, and more.
In PNAS this week: genome and transcriptome of the Asian tiger mosquito, TB diversity and virulence in Inuit populations, and more.
The company plans to establish a clinical laboratory to offer its Gensignia miRNA Signature Classifier for Lung Cancer Test, as well as other tests in the future.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.